Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M Chandran
Is It Necessary to Use Three Mandatory Loading Doses When Commencing Therapy for Neovascular Age-Related Macular Degeneration Using Bevacizumab? (BeMOc Trial)
Eye
Medicine
Arts
Sensory Systems
Ophthalmology
Humanities
Related publications
Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration
Archives of Ophthalmology
Contrast Sensitivity Outcomes in the ABC Trial: A Randomized Trial of Bevacizumab for Neovascular Age-Related Macular Degeneration
Investigative Ophthalmology and Visual Science
Molecular Neuroscience
Ophthalmology
Sensory Systems
Cellular
Aflibercept for Neovascular Age-Related Macular Degeneration
Cochrane Database of Systematic Reviews
Single-Session Photodynamic Therapy Combined With Intravitreal Bevacizumab and Triamcinolone for Neovascular Age-Related Macular Degeneration
BMC Ophthalmology
Medicine
Ophthalmology
Macular Atrophy in Neovascular Age Related Macular Degeneration
Journal of Clinical Review & Case Reports
IL-18 Is Not Therapeutic for Neovascular Age-Related Macular Degeneration
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Neovascular Age-Related Macular Degeneration Is Associated With Cataract Surgery
Acta Ophthalmologica
Medicine
Ophthalmology
Ranibizumab Versus Verteporfin for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine
Medicine
One-Year Outcomes of 1 Dose Versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial
Journal of Ophthalmology
Ophthalmology
